# The Calcium Connection: Explaining Motor Neuron Vulnerability in ALS

**Authors:** Tristan Dellazizzo Toth, Silvano Bond, Smita Saxena

PMC · DOI: 10.3390/cells15040322 · 2026-02-09

## TL;DR

This paper explores how calcium imbalances contribute to motor neuron death in ALS, offering insights into disease mechanisms and potential treatments.

## Contribution

The paper synthesizes current evidence on calcium dysregulation's role in ALS pathogenesis and identifies therapeutic targets.

## Key findings

- Calcium dysregulation affects cellular, synaptic, and network levels in ALS progression.
- Calcium imbalance is linked to metabolic dysfunction, ER stress, and neuron-glia interactions.
- Elevated neuronal activity may have neuroprotective effects despite calcium overload risks.

## Abstract

What are the main findings?
Calcium dysregulation plays a key role in ALS, acting on the cellular, synaptic, and network levels to drive disease progression.Calcium dysregulation is linked to metabolic dysfunction, ER stress, and aberrant neuron-glia interactions.

Calcium dysregulation plays a key role in ALS, acting on the cellular, synaptic, and network levels to drive disease progression.

Calcium dysregulation is linked to metabolic dysfunction, ER stress, and aberrant neuron-glia interactions.

What are the implications of the main findings?
Understanding the role of calcium dysregulation in ALS can elucidate the causes of the selective vulnerability of classes of motor neurons in ALSTargeting calcium dysregulation can lead to the development of new therapeutic interventions.

Understanding the role of calcium dysregulation in ALS can elucidate the causes of the selective vulnerability of classes of motor neurons in ALS

Targeting calcium dysregulation can lead to the development of new therapeutic interventions.

ALS is a severe neuromuscular disease classically characterized by the progressive loss of motor neurons, leading to incremental muscle weakness and eventually death. Current treatment options for ALS have proven to have limited effect, merely delaying the progression of symptoms and prolonging patient survival. This motor neuron subtype-related differential vulnerability has been linked to neuron excitability, metabolism, and protein aggregation. Calcium dysregulation, which serves as an important second messenger in neural signaling pathways, has been implicated in each of these mechanisms and represents a potential target for therapeutic intervention. Armed with cutting-edge tools for visualizing and recording calcium transients in vivo, ALS researchers have delved deeper into the role of calcium dysregulation in disease in recent years. Vulnerable motor neuron populations display an excess of calcium-permeable ion channels together with reduced expression of calcium-binding proteins, generating a cellular environment primed for excitotoxic stress. Loss of inhibitory synaptic input further heightens susceptibility to calcium overload. Paradoxically, some evidence suggests that elevated neuronal activity can exert neuroprotective effects, highlighting the complexity of activity-dependent calcium signaling in ALS. Additionally, ALS-related toxic protein accumulation disrupts calcium homeostasis, contributing to endoplasmic reticulum stress and mitochondrial dysfunction. Emerging data indicate that calcium dysregulation impairs neuron-glia communication, amplifying neuroinflammation and accelerating disease progression. This review aims to synthesize current evidence on how calcium imbalance contributes to motor neuron vulnerability and degeneration in ALS. By exploring the cellular, synaptic, and network-level mechanisms of calcium dysregulation in ALS, the review examines its interplay with mitochondrial and ER stress and explores its impact on neuron-glia interactions with the aim of synthesizing key mechanistic insights into the disease pathogenesis and therapeutic targets.

## Linked entities

- **Diseases:** ALS (MONDO:0004976)

## Full-text entities

- **Genes:** CALB2 (calbindin 2) [NCBI Gene 794] {aka CAB29, CAL2, CR}, ADARB1 (adenosine deaminase RNA specific B1) [NCBI Gene 104] {aka ADAR2, DRABA2, DRADA2, NEDHYMS, RED1}, GRIA1 (glutamate ionotropic receptor AMPA type subunit 1) [NCBI Gene 2890] {aka GLUH1, GLUR1, GLURA, GluA1, HBGR1, MRD67}, VCP (valosin containing protein) [NCBI Gene 7415] {aka CDC48, FTDALS6, TERA, p97}, Sod1 (Superoxide dismutase 1) [NCBI Gene 39251] {aka 24492, CG11793, Cu, Cu-Zn SOD, Cu-Zn-SOD, Cu/Zn SOD}, KCNN4 (potassium calcium-activated channel subfamily N member 4) [NCBI Gene 3783] {aka DHS2, IK, IK1, IKCA1, KCA4, KCa3.1}, GRIA2 (glutamate ionotropic receptor AMPA type subunit 2) [NCBI Gene 2891] {aka GLUR2, GLURB, GluA2, GluR-K2, HBGR2, NEDLIB}, HSPA9 (heat shock protein family A (Hsp70) member 9) [NCBI Gene 3313] {aka CRP40, CSA, EVPLS, GRP-75, GRP75, HEL-S-124m}, FUS (FUS RNA binding protein) [NCBI Gene 2521] {aka ALS6, ETM4, FUS1, HNRNPP2, POMP75, TLS}, PVALB (parvalbumin) [NCBI Gene 5816] {aka D22S749}, Tardbp (TAR DNA binding protein) [NCBI Gene 230908] {aka 1190002A23Rik, TDP-43, Tdp43}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, C9orf72 (C9orf72-SMCR8 complex subunit) [NCBI Gene 203228] {aka ALSFTD, DENND9, DENNL72, FTDALS, FTDALS1}, CanA1 (Calcineurin A1) [NCBI Gene 43670] {aka CAN A1/PP2B, CG1455, CNA1, CaN, Can, CnA}, MTF1 (metal regulatory transcription factor 1) [NCBI Gene 4520] {aka MTF-1, ZRF}, CALB1 (calbindin 1) [NCBI Gene 793] {aka CALB, D-28K}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Sod1 (superoxide dismutase 1, soluble) [NCBI Gene 20655] {aka B430204E11Rik, Cu/Zn-SOD, CuZnSOD, Ipo-1, Ipo1, SODC}, TARDBP (TAR DNA binding protein) [NCBI Gene 23435] {aka ALS10, TDP-43}, CDNF (cerebral dopamine neurotrophic factor) [NCBI Gene 441549] {aka ARMETL1}, PLA2G4A (phospholipase A2 group IVA) [NCBI Gene 5321] {aka GURDP, PLA2G4, cPLA2, cPLA2-alpha}, GSS (glutathione synthetase) [NCBI Gene 2937] {aka CNSHA6, GSHS, HEL-S-64p, HEL-S-88n}, Stim1 (stromal interaction molecule 1) [NCBI Gene 20866] {aka SIM}, Atp2a3 (ATPase, Ca++ transporting, ubiquitous) [NCBI Gene 53313] {aka SERCA3b, Serca3}, CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}, Orai1 (ORAI calcium release-activated calcium modulator 1) [NCBI Gene 109305] {aka D730049H07Rik, Tmem142a, orai-1}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, TBPH (TAR DNA-binding protein-43 homolog) [NCBI Gene 37781] {aka CG10327, Dmel\CG10327, TDP-43, TDP43, TDPH, dTBPH}, NPY (neuropeptide Y) [NCBI Gene 4852] {aka PYY4}, GABARAP (GABA type A receptor-associated protein) [NCBI Gene 11337] {aka ATG8A, GABARAP-a, MM46}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, Fus (fused in sarcoma) [NCBI Gene 233908] {aka D430004D17Rik, D930039C12Rik, Fus1, Tls}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, DNAH8 (dynein axonemal heavy chain 8) [NCBI Gene 1769] {aka ATPase, SPGF46, hdhc9}
- **Diseases:** respiratory failure (MESH:D012131), motor neuron impairments (MESH:D016472), paralysis (MESH:D010243), Fatigue (MESH:D005221), Paget disease (MESH:C537701), neuron dysfunction (MESH:D009461), metabolic dysregulation (MESH:D021081), muscle fasciculations (MESH:D005207), calcium overload (MESH:D019190), spasticity (MESH:D009128), neurodegeneration (MESH:D019636), excitotoxic injury (MESH:D014947), muscle atrophy (MESH:D009133), inflammatory (MESH:D007249), Parkinson's (MESH:D010300), muscle denervation (MESH:D019042), mitochondrial dysfunction (MESH:D028361), muscle weakness (MESH:D018908), Alzheimer's (MESH:D000544), neurotoxic (MESH:D020258), atrophy (MESH:D001284), neuroinflammation (MESH:D000090862), spinal muscular atrophy (MESH:D009134), Calcium (MESH:D002128), degeneration (MESH:D009410), dysfunction (MESH:D006331), sALS (MESH:C531617), neuromuscular disease (MESH:D009468), FTD (MESH:D057180), motor dysfunction (MESH:D000068079), ALS (MESH:D008113), cognitive decline (MESH:D003072), ALS (MESH:D000690), demyelination (MESH:D003711), Inclusion Body Myopathy (MESH:C536816), death (MESH:D003643)
- **Chemicals:** kaempferol (MESH:C006552), salubrinal (MESH:C496827), Acetylcholine (MESH:D000109), pimozide (MESH:D010868), glutamate (MESH:D018698), GABA (MESH:D005680), oxygen (MESH:D010100), GM1 ganglioside (MESH:D005677), lomerizine (MESH:C052424), ATP (MESH:D000255), Riluzole (MESH:D019782), heavy metal (MESH:D019216), Calcium (MESH:D002118), NO (MESH:D009614), hydrogen peroxide (MESH:D006861), Ca2+ (-), superoxide (MESH:D013481), AMPA (MESH:D018350), sodium (MESH:D012964)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** P525L, G93A, A-to-I

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12939783/full.md

---
Source: https://tomesphere.com/paper/PMC12939783